We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

12 hedge funds and large institutions have $536K invested in InMed Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

9% more funds holding

Funds holding: 11 → 12 (+1)

0.01% less ownership

Funds ownership: 0.01% → 0.01% (-0.01%)

45% less capital invested

Capital invested by funds: $981K → $536K (-$445K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$319K
2
Two Sigma Investments
Two Sigma Investments
New York
+$204K
3
Renaissance Technologies
Renaissance Technologies
New York
+$68.1K
4
RFA
Reilly Financial Advisors
California
+$774

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$893K
2
VF
Virtu Financial
New York
-$20K
3
Citadel Advisors
Citadel Advisors
Florida
-$10.8K
4
UBS Group
UBS Group
Switzerland
-$9K
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
1
Two Sigma Advisers
New York
$270K +$319K +412 New
Two Sigma Investments
2
Two Sigma Investments
New York
$172K +$204K +263 New
Renaissance Technologies
3
Renaissance Technologies
New York
$58K +$68.1K +88 New
Citadel Advisors
4
Citadel Advisors
Florida
$14K -$10.8K -14 -39%
Creative Planning
5
Creative Planning
Kansas
$14K – – –
TWC
6
TD Waterhouse Canada
Ontario, Canada
$3.68K +$3.1K +4 New
AWM
7
AllSquare Wealth Management
New York
$1K – – –
Osaic Holdings
8
Osaic Holdings
Arizona
$1K – – –
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$1K – – –
RFA
10
Reilly Financial Advisors
California
$1K +$774 +1 New
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Quebec, Canada
$669 – – –
AC
12
Armistice Capital
New York
– -$893K -1,020 Closed
VF
13
Virtu Financial
New York
– -$20K -23 Closed
UBS Group
14
UBS Group
Switzerland
– -$9K -10 Closed
PNC Financial Services Group
15
PNC Financial Services Group
Pennsylvania
– -$3K -4 Closed
FF
16
FourThought Financial
Florida
– -$1K -1 Closed
NWM
17
Navigation Wealth Management
Colorado
– -$1K – –
National Bank of Canada
18
National Bank of Canada
Quebec, Canada
– +$774 +1 New

INM Hedge Fund Activity: Q4 2021 in Review

12 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q4 2021, worth a combined $536K — down 45% from $981K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new INM positions and 5 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $319K. The largest seller was Armistice Capital, exiting entirely with an estimated $893K sold.

  • 12 institutional investors held InMed Pharmaceuticals (INM) as of Q4 2021, up from 11 in Q3 2021.
  • Funds reported $536K of InMed Pharmaceuticals stock for Q4 2021, down 45% quarter-over-quarter.
  • 6 funds opened new InMed Pharmaceuticals positions in Q4 2021 and 5 closed out, a net change of +1 holder.
  • The largest InMed Pharmaceuticals buyer in Q4 2021 was Two Sigma Advisers, an estimated $319K added.
  • The largest InMed Pharmaceuticals seller in Q4 2021 was Armistice Capital, an estimated $893K sold.

Based on aggregated 13F filings for Q4 2021.